Review



software version 7.10.3  (MetaMorph Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    MetaMorph Inc software version 7.10.3
    Systemic administration of iPS-MSCs improves cardiac function in a rat ischemic cardiomyopathy model. (a) Representative images of M-mode echocardiography in the control group, iPS-MSC group, and siAlix-MSC group. (b) Ejection fraction (EF), left <t>ventricular</t> end-diastolic diameter (LVDd), and left ventricular end-diastolic diameter (LVD) before and 1 week after sequential administration of cells in each group (control group, n = 10; iPS-MSC group, n = 12; siAlix-MSC group; n = 9). Data are presented as mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001 between groups, by one-way analysis of variance with post hoc Turkey's multiple comparisons.
    Software Version 7.10.3, supplied by MetaMorph Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/software version 7.10.3/product/MetaMorph Inc
    Average 90 stars, based on 1 article reviews
    software version 7.10.3 - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Systemic administration of induced pluripotent stem cell-derived mesenchymal stem cells improves cardiac function through extracellular vesicle-mediated tissue repair in a rat model of ischemic cardiomyopathy"

    Article Title: Systemic administration of induced pluripotent stem cell-derived mesenchymal stem cells improves cardiac function through extracellular vesicle-mediated tissue repair in a rat model of ischemic cardiomyopathy

    Journal: Regenerative Therapy

    doi: 10.1016/j.reth.2024.12.008

    Systemic administration of iPS-MSCs improves cardiac function in a rat ischemic cardiomyopathy model. (a) Representative images of M-mode echocardiography in the control group, iPS-MSC group, and siAlix-MSC group. (b) Ejection fraction (EF), left ventricular end-diastolic diameter (LVDd), and left ventricular end-diastolic diameter (LVD) before and 1 week after sequential administration of cells in each group (control group, n = 10; iPS-MSC group, n = 12; siAlix-MSC group; n = 9). Data are presented as mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001 between groups, by one-way analysis of variance with post hoc Turkey's multiple comparisons.
    Figure Legend Snippet: Systemic administration of iPS-MSCs improves cardiac function in a rat ischemic cardiomyopathy model. (a) Representative images of M-mode echocardiography in the control group, iPS-MSC group, and siAlix-MSC group. (b) Ejection fraction (EF), left ventricular end-diastolic diameter (LVDd), and left ventricular end-diastolic diameter (LVD) before and 1 week after sequential administration of cells in each group (control group, n = 10; iPS-MSC group, n = 12; siAlix-MSC group; n = 9). Data are presented as mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001 between groups, by one-way analysis of variance with post hoc Turkey's multiple comparisons.

    Techniques Used: Control



    Similar Products

    software version 7.10.3  (MetaMorph Inc)
    90
    MetaMorph Inc software version 7.10.3
    Systemic administration of iPS-MSCs improves cardiac function in a rat ischemic cardiomyopathy model. (a) Representative images of M-mode echocardiography in the control group, iPS-MSC group, and siAlix-MSC group. (b) Ejection fraction (EF), left <t>ventricular</t> end-diastolic diameter (LVDd), and left ventricular end-diastolic diameter (LVD) before and 1 week after sequential administration of cells in each group (control group, n = 10; iPS-MSC group, n = 12; siAlix-MSC group; n = 9). Data are presented as mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001 between groups, by one-way analysis of variance with post hoc Turkey's multiple comparisons.
    Software Version 7.10.3, supplied by MetaMorph Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/software version 7.10.3/product/MetaMorph Inc
    Average 90 stars, based on 1 article reviews
    software version 7.10.3 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Systemic administration of iPS-MSCs improves cardiac function in a rat ischemic cardiomyopathy model. (a) Representative images of M-mode echocardiography in the control group, iPS-MSC group, and siAlix-MSC group. (b) Ejection fraction (EF), left ventricular end-diastolic diameter (LVDd), and left ventricular end-diastolic diameter (LVD) before and 1 week after sequential administration of cells in each group (control group, n = 10; iPS-MSC group, n = 12; siAlix-MSC group; n = 9). Data are presented as mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001 between groups, by one-way analysis of variance with post hoc Turkey's multiple comparisons.

    Journal: Regenerative Therapy

    Article Title: Systemic administration of induced pluripotent stem cell-derived mesenchymal stem cells improves cardiac function through extracellular vesicle-mediated tissue repair in a rat model of ischemic cardiomyopathy

    doi: 10.1016/j.reth.2024.12.008

    Figure Lengend Snippet: Systemic administration of iPS-MSCs improves cardiac function in a rat ischemic cardiomyopathy model. (a) Representative images of M-mode echocardiography in the control group, iPS-MSC group, and siAlix-MSC group. (b) Ejection fraction (EF), left ventricular end-diastolic diameter (LVDd), and left ventricular end-diastolic diameter (LVD) before and 1 week after sequential administration of cells in each group (control group, n = 10; iPS-MSC group, n = 12; siAlix-MSC group; n = 9). Data are presented as mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001 between groups, by one-way analysis of variance with post hoc Turkey's multiple comparisons.

    Article Snippet: The fibrotic area was calculated as the ratio of the total fibrotic area to the total left ventricular area using the MetaMorph software (version 7.10.3).

    Techniques: Control